Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.

Froissart, Antoine; Buffet, Marc; Veyradier, Agnès; Poullin, Pascale; Provôt, François; Malot, Sandrine; Schwarzinger, Michael; Galicier, Lionel; Vanhille, Philippe; Vernant, Jean-Paul; Bordessoule, Dominique; Guidet, Bertrand; Azoulay, Elie; Mariotte, Eric; Rondeau, Eric; Mira, Jean-Paul; Wynckel, Alain; Clabault, Karine; Choukroun, Gabriel; Presne, Claire; Pourrat, Jacques; Hamidou, Mohamed; Coppo, Paul.
Crit Care Med; 40(1): 104-11, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21926591